ArticlePlastic and reconstructive surgery. Global open2026
Bacteriophage Therapy for Breast Implants: A Translational Perspective and Future Directions.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast implant infection and capsular contracture remain significant complications of implant-based breast surgery, largely driven by bacterial biofilm formation. Despite adherence to perioperative antibiotic prophylaxis and pocket irrigation protocols, established biofilms are difficult to eradicate and frequently necessitate implant removal, resulting in reconstructive, psychological, and financial consequences for patients. In the context of rising antimicrobial resistance and the limited efficacy of antibiotics against biofilm-associated bacteria, bacteriophage therapy has emerged as a biologically compelling adjunctive strategy. Bacteriophages are viruses that selectively infect and lyse bacteria, with a demonstrated capacity to penetrate biofilms and disrupt structured microbial communities. Encouraging clinical outcomes have been reported in orthopedic prosthetic joint infections and vascular graft infections, where phage therapy, often combined with antibiotics, has achieved high rates of bacterial eradication and implant salvage. However, its application in implant-based breast surgery remains largely unexplored, with evidence currently limited to a single experimental study. This translational perspective reviews the biological rationale for bacteriophage use in breast implant-associated biofilm, examines parallels from other implant specialties, and outlines potential preventive and therapeutic applications within breast surgery. Key barriers, including regulatory challenges, phage specificity, delivery strategies within the implant pocket, immune considerations, and the potential emergence of phage resistance, are critically discussed. Bridging this translational gap will require implant-specific biofilm models, standardized delivery protocols, and early-phase clinical evaluation. Bacteriophage therapy represents a promising yet underdeveloped strategy that may expand future options for implant infection management and salvage and, potentially, capsular contracture prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.